2007: RA: Clinical Aspects III

RA: Clinical Aspects III

Saturday, November 10, 2007

1806

Validation of a Disease Activity Score Using Patient Derived Joint Counts

1807

Relationship Between Residual Functional Disability and Residual Disease Activity in Patients With Early Rheumatoid Arthritis Who Achieved a Remission-like State in the PREMIER Study

1808

Is there a Gender Bias in Prescribing Anti-TNFs to Patients with RA?

1809

An Index Based on Only Patient Reported Outcome (PRO) Measures, Without Formal Joint Counts, Routine Assessment of Patient Index Data (RAPID) Classifies Patients into 4 Severity Categories which are Similar to Disease Activity Score (DAS28) and Clinical D

1810

Recognition of Remission or Near Remission Status at the Conclusion of the AIM and ATTAIN Abatacept Clinical Trials according to an Index of Only the 3 Patient Measures in the Rheumatoid Arthritis (RA) Core Data Set, Without Joint Counts, Routine Assessme

1811

Real-Time Assessment of Disease Activity in Rheumatoid Arthritis (RADARA): Use of Threshold Criteria Improves Specificity of Composite Clinical Outcome Measures

1812

Validity of the Rheumatoid Arthritis Disease Activity Index in Early Inflammatory Arthritis

1813

Evaluation of the Onset of Clinical Response in Abatacept-Treated Rheumatoid Arthritis Patients Using the Simplified Disease Activity Index and the Clinical Disease Activity Index

1814

Novel Approach to Assess Patient Derived Measures in Rheumatoid Arthritis

1815

Digital X-ray Radiogrammetry: A Promising Predictor of Joint Destruction in Early Ra

1816

Measuring Radiological Disease Progression in Early Rheumatoid Arthritis - The Effect of Scoring Methods

1817

Defining Change in Disease Activity Parameters Associated with Loss of Response Over Time in RA Patients

1818

Extra-articular Manifestations in a Community Based Sample of Patients with Rheumatoid Arthritis: Incidence and Relation to Treatment with TNF Inhibitors

1819

The Disease Activity Score (DAS) with Extended Joint Counts in Rheumatoid Arthritis: Update and Validation of the Original DAS Formula

1820

Does Training of Patients Using a Computer Assisted Patient Reported Outcome Tool in Rheumatoid Arthritis Persist Between Visits?

1821

Patient-Reported Outcomes (PROs) in Assessment of Patients with Rheumatoid Arthritis (RA) Seen in Standard Rheumatology Care in 21 Countries in the QUEST-RA Study

1822

Development of a Health Care Utilization Database Index for Rheumatoid Arthritis Severity

1823

Quality of Healthcare for Patients with Rheumatoid Arthritis has Improved: Results from the German Rheumatoid Arthritis Population Survey (GRAPS)

1824

The Impact of Foot Compromise in Patients with Rheumatoid Arthritis

1825

Would prior testing of Anti-Cyclic Citrullinated Antibodies (anti CCP) Help with Decision Making at the First Visit to an Early Arthritis Clinic?

1826

The Significance of the Second and Third Generations of Anti-Cyclic Citrullinated Peptides Antibodies among Various Serological Tests for Rheumatoid Arthritis

1827

Prediction of Therapy Outcome of Etanercept Treated Patients with Rheumatoid Arthritis (RA) Based on Pre-Treatment Anti-Cyclic Citrullinated Peptide (CCP) Antibody Levels

1828

Two Novel Assays-Third Generation Cyclic Citrullinated Peptides and Antibodies Against Modified Citrullinated Vimentin in the Diagnosis of Rheumatoid Arthritis and Relation with Disease Activity

1829

Discrepancies between Acpa Tests: Do All Anti-citrullinated Protein/Peptide Antibody (acpa) Tests Measure the Same?

1830

Anti-CCP Antibody : Is it a Marker of Structural Joint Damage in Early Rheumatoid Arthritis?

1831

The Value of Antibodies to Mutated Citrullinated Vimentin in Early Arthitis

1832

Sensitivity and Specificity of Second- and Third-Generation Cyclic Citrullinated Peptide Antibody Assays

1833

Anti-CCP and Rheumatoid Factor Expression in Rheumatoid Arthritis; an Investigation of the Effect of Rheumatoid Factor on the ELISA quantitation of IgG anti-CCP

1834

Patients with Undifferentiated Arthritis Showing High Titer of Anti-CCP2 Antibodies Develop RA within One Year

1835

Sera from Patients with Pulmonary Tuberculosis are Frequently Positive in Anti-CCP ELISA but also React with Unmodified Arginine-Containing Peptide

1836

Rheumatoid Disease Process and/or Therapy Differentially Impact on IgM and IgA Rheumatoid Factor Responses in Affected Native Americans When Compared to Unaffected High Risk Relatives

1837

The Inova CCP3.1 IgA/IgG ELISA Represents Significant Improvement in the Laboratory Diagnosis of Rheumatoid Arthritis

1838

No Association between Levels of Auto-Antibodies and the Improvement of RA during Pregnancy

1839

A Novel Imaging Technology for Joint Assessment in Arthritis: Results of a Feasibility Study

1840

Prognostic Evaluation of Undifferentiated Arthritis (UA) at Baseline Through Magnetic Resonance Imaging (MRI)-Detection of Early Join Damages and Serologic Variables: Results from the Prospective Clinical Study

1841

Ultrasound at Presentation Predicts Clinical Outcome in Very Early Inflammatory Patients

1842

How Can Synovitis Detection by Ultrasonography Modify DAS28?

1850

Cricoarytenoid (ca) and Laryngeal Rheumatoid Arthritis (RA): Their Clinical, Functional and Imaging Findings

1863

Validation of the self-report of Rheumatoid Arthritis and Systemic Lupus Erythematosus: The Women’s Health Initiative

1864

The Association between NT-proBNP and Measures of Disease Activity in 238 Patients with Rheumatoid Arthritis: A 10-year Longitudinal Study

1877

High Levels of Serum Cartilage Oligomeric Matrix Protein (comp) in Early Rheumatoid Arthritis (ra) Associate with Anti-Cyclic Citrullinated Peptide (ccp)-Negative and Anti-Collagen Type Ii (cii) Positive Disease and with Low Level Activity During Follow-u

1878

Genome-Wide Phararmacogenomics in Anti-TNF Therapy of Rheumatoid Arthritis: Implications for Their Efficacy and Adverse Reactions

1879

Circulating Survivin is a Negative Predictor of Remission in Early Ra

1880

Serum Cytokine Levels Determined by Multiplex Assays and Clinical Characteristics in Patients with Rheumatoid Arthritis

1881

Serum IL-6 and YKL-40 Levels in Early Rheumatoid Arthritis are Associated with Disease Activity, Treatment Response and Radiographic Outcome

1882

Patients with Destructive Joint-Disease Have Increased MMP-Mediated Aggrecan Degradation

1883

A Transmembrane Polymorphism in FcγRIIb (FCGR2B) Is Associated with Rheumatoid Factor Production and Disease Severity in Taiwanese RA Patients

1884

Higher Levels of Leptin in Obese Patients Correlate with Rheumatoid Arthritis Activity

1885

The Effect of Hormone Replacement Therapy on Soluble RAGE Levels in Postmenopausal RA Patients

1886

Synovial PPARγ Expression as a Tissue Biomarker in Rheumatoid Arthritis

1887

Usefulness of Multiple Single Nucleotide Polymorphisms Detection by a DNA Array in the Prediction of Functional Impairment and Remission Status in Rheumatoid Arthritis

1888

Rheumatoid Arthritis and Access to Care in the GTA

1889

Evaluation of Selected Rheumatoid Arthritis Activity Scores for Office Based Assessment

1890

Characterization of Synovial Tissue and Plasma Biomarkers and their Relationship to Rheumatoid Arthritis Disease Activity

1891

Rheumatoid Arthritis Diagnosis: A Comparative Study of Second and Third Generation Anti-Cyclic Citrullinated Peptide (CCP) Antibody Elisas

1892

Can we Predict Structural Damage Progression at 2 Years in Very Early Arthritis ? Value of Bone and Cartilage Markers in the Conservatively Treated Community-Based Inceptive VErA Cohort

1893

Comparison of Anti-Mutated Citrullinated Vimentin with Anti-Cyclic Citrullinated Peptide and Rheumatoid Factors for the Diagnosis of Rheumatoid Arthritis

1894

Usefulness of Magnetic Resonance Imaging of the Hand Versus Anti-Cyclic Citrullinated Peptide Antibody Test to Confirm Diagnosis in Patients with Clinical Suspicion of Early Rheumatoid Arthritis in the Absence of Rheumatoid Factor and Radiographic Erosion

1895

Relationship between Biomarkers for Cartilage and Bone and Joint Counting in Patients with Rheumatoid Arthritis

1896

Serum CX3CL1 Levels are Predictive of the Response to Infliximab Therapy in Patients with Rheumatoid Arthritis

1897

Usage of High Sensitivity CRP Test Together with Anti-Cyclic Citrullinated Peptide Antibody Significantly Raised the Predictive Value for Rheumatoid Arthritis

1898

Anti-Cyclic Citrulline Peptide Antibodies (Anti-CCP) and Anti-Citrullinated Vimentin in Patients with Systemic Rheumatic Diseases Different to Rheumatoid Arthritis (RA)

1899

Increased Concentration of Plasma Pentraxin 3 in Rheumatoid Arthritis: Relationship to Chronic Inflammation, Bone Destruction and Atherosclerosis

1900

Anti Cyclic Citrullinated Peptide Antibodies (anti-CCP) and Rheumatoid Factor in Established Rheumatoid Arthritis: A Real World Experience

1901

Antibodies to Citrullinated Human Fibrin Synthetic Peptides: Diagnostic Value in Rheumatoid Arthritis

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>